Farms.com Home   Ag Industry News

CGC licencing change updates

CGC licencing change updates
Oct 30, 2025
By Diego Flammini
Assistant Editor, North American Content, Farms.com

One company received a licence, while another had its licence class changed

A company in B.C. recently received a licence from the Canadian Grain Commission.

As of Oct. 22, Seatarra Ingredient Alliance West Ltd. at 305-4190 Lougheed Highway in Burnaby, B.C., has a grain dealer licence.

This type of licence is for “a person who, for reward, on his own behalf or the behalf of another person, deals in or handles western grain,” the CGC says.

Headquartered in Ontario, Seatarra partners with businesses across North America “supplying high-quality ingredients for both pet and human food,” its website says.

So far in 2025, the CGC has issued 19 new licences, compared with 20 licences at the same time in 2024.

On Oct. 23, two grain companies underwent name changes.

Pacific Elevators Limited, and Viterra Canada, both in Regina, Sask., are now Bunge Canada Inc., the CGC’’s website states.

And a Manitoba company had its licence class change recently.

On Oct. 21, Paterson Grain location in Culross, Man., had its licence changed from a primary elevator licence to a process elevator licence.

A primary elevator licence goes to “an operator of an elevator which primary receives grain directly from producers, for either both storage or forwarding,” according to the CGC.

And a process elevator licence “may be issued to an operator of an elevator which receives and stores grain for direct manufacture or processing into other products.”

 


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.